Wong ASC - Search Results

1

Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.

Huang Y, Soon YY, Aminkeng F, Tay SH, Ang Y, Kee ACL, Goh BC, Wong ASC, Soo RA. Huang Y, et al. Among authors: wong asc. Int J Cancer. 2022 Feb 15;150(4):636-644. doi: 10.1002/ijc.33822. Epub 2021 Oct 13. Int J Cancer. 2022. PMID: 34562273 Free article.

2

Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma.

Wong AS, Soo RA, Lu JJ, Loh KS, Tan KS, Hsieh WS, Shakespeare TP, Chua ET, Lim HL, Goh BC. Wong AS, et al. Ann Oncol. 2006 Jul;17(7):1152-7. doi: 10.1093/annonc/mdl090. Epub 2006 May 9. Ann Oncol. 2006. PMID: 16684789 Free article. Clinical Trial.

3

A patient with pembrolizumab-induced fatal polymyositis.

Tay SH, Wong AS, Jeyasekharan AD. Tay SH, et al. Eur J Cancer. 2018 Mar;91:180-182. doi: 10.1016/j.ejca.2017.12.019. Epub 2018 Jan 10. Eur J Cancer. 2018. PMID: 29329695 No abstract available.

4

Radical radiotherapy in older patients with muscle invasive bladder cancer.

Wujanto C, Tey J, Chia D, Ho F, Ooi KH, Wong AS, Soon YY, Lim K. Wujanto C, et al. J Geriatr Oncol. 2019 Mar;10(2):292-297. doi: 10.1016/j.jgo.2018.10.015. Epub 2019 Jan 8. J Geriatr Oncol. 2019. PMID: 30630748

5

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.

Huang Y, Zhao JJ, Soon YY, Kee A, Tay SH, Aminkeng F, Ang Y, Wong ASC, Bharwani LD, Goh BC, Soo RA. Huang Y, et al. Among authors: wong asc. Cancers (Basel). 2023 May 12;15(10):2733. doi: 10.3390/cancers15102733. Cancers (Basel). 2023. PMID: 37345072 Free PMC article.

6

Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer.

Zee YK, Chin TM, Wong AS. Zee YK, et al. J Clin Oncol. 2009 Oct 20;27(30):e145-6. doi: 10.1200/JCO.2009.22.4501. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667265 No abstract available.

7

Pushing the limits of immune-related response: a case of "extreme pseudoprogression".

Wong AS, Thian YL, Kapur J, Leong CN, Kee P, Lee CT, Lee MB. Wong AS, et al. Cancer Immunol Immunother. 2018 Jul;67(7):1105-1111. doi: 10.1007/s00262-018-2167-3. Epub 2018 May 4. Cancer Immunol Immunother. 2018. PMID: 29728723 Free PMC article.

8

Reply to "Pseudoprogression": more than semantics.

Wong AS, Lee MB. Wong AS, et al. Cancer Immunol Immunother. 2018 Sep;67(9):1475. doi: 10.1007/s00262-018-2210-4. Epub 2018 Jul 30. Cancer Immunol Immunother. 2018. PMID: 30062556 Free PMC article. No abstract available.

9

High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis.

Yoon KH, Wong A, Shakespeare T, Sivalingam P. Yoon KH, et al. Lupus. 2003;12(2):112-6. doi: 10.1191/0961203303lu328oa. Lupus. 2003. PMID: 12630755

10

Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours.

Salto-Tellez M, Nga ME, Han HC, Wong AS, Lee CK, Anuar D, Ng SS, Ho M, Wee A, Chan YH, Soong R. Salto-Tellez M, et al. Br J Cancer. 2007 Mar 12;96(5):776-82. doi: 10.1038/sj.bjc.6603551. Epub 2007 Feb 13. Br J Cancer. 2007. PMID: 17299397 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34 results

Search Page